Abbvie Inc

-0.57 (-0.38%)
4:07:03 PM EDT: $150.10 +0.10 (+0.07%)
Products, Regulatory

Abbvie Inc - Upadacitinib (RINVOQ®) Achieved Clinical Remission And Endoscopic Response At One Year In Phase 3 Maintenance Study In Patients With Crohn's Disease

Published: 05/11/2022 12:59 GMT
Abbvie Inc (ABBV) - Abbvie Inc - Upadacitinib (rinvoq®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients With Crohn's Disease.
Abbvie Inc - Safety Results in Study Were Generally Consistent With Known Profile of Upadacitinib, With No New Safety Risks Observed.
Abbvie Inc - Results Showed That More Patients Treated With Either Dose of Upadacitinib Achieved Co-primary Endpoints at One Year Compared to Placebo.
Abbvie Inc - No Deaths Were Reported Throughout Study and No New Safety Risks Were Identified.